Baseline characteristics
| . | Early removal (n = 255) . | Delayed or no removal (n = 225) . | P . | Removal only (n = 116) . |
|---|---|---|---|---|
| Age, mean (SD) | 54 (16) | 51 (15) | .12* | 50 (18) |
| Male, n (%) | 143 (56) | 121 (54) | .61† | 63 (54) |
| Hematologic malignancy, n (%) | ||||
| Leukemia/MDS/MPN | 121 (47) | 83 (37) | .01† | 83 (72) |
| Lymphoma | 86 (34) | 106 (47) | 16 (14) | |
| Plasma cell dyscrasia | 48 (19) | 36 (16) | 17 (15) | |
| Catheter type, n (%) | ||||
| PICC | 189 (74) | 110 (49) | <.001† | 96 (83) |
| PORT-a-cath | 12 (5) | 49 (22) | 3 (2) | |
| Tunneled | 54 (21) | 66 (29) | 17 (15) | |
| DVT location, n (%) | ||||
| Brachial | 25 (10) | 13 (6) | <.001ठ| 25 (22) |
| Axillary | 58 (23) | 30 (13) | 33 (28) | |
| Subclavian | 108 (42) | 80 (36) | 40 (34) | |
| Internal jugular | 48 (19) | 80 (36) | 16 (14) | |
| Superior vena cava | 6 (2) | 4 (2) | 2 (2) | |
| Brachiocephalic | 8 (3) | 16 (7) | 0 | |
| Other | 2 (1) | 2 (1) | 0 | |
| Platelet count(× 109/L), median (IQR) | 125 (61-208) | 138 (72-207) | .25§ | 30 (18-71) |
| Anticoagulation, n (%) | ||||
| LMWH | 192 (75) | 178 (79) | .20‡ | NA |
| Bridge to VKA | 24 (9) | 10 (4) | ||
| UFH | 23 (9) | 24 (11) | ||
| Aspirin | 1 (0.4) | 0 | ||
| Other | 15 (6) | 13 (6) |
| . | Early removal (n = 255) . | Delayed or no removal (n = 225) . | P . | Removal only (n = 116) . |
|---|---|---|---|---|
| Age, mean (SD) | 54 (16) | 51 (15) | .12* | 50 (18) |
| Male, n (%) | 143 (56) | 121 (54) | .61† | 63 (54) |
| Hematologic malignancy, n (%) | ||||
| Leukemia/MDS/MPN | 121 (47) | 83 (37) | .01† | 83 (72) |
| Lymphoma | 86 (34) | 106 (47) | 16 (14) | |
| Plasma cell dyscrasia | 48 (19) | 36 (16) | 17 (15) | |
| Catheter type, n (%) | ||||
| PICC | 189 (74) | 110 (49) | <.001† | 96 (83) |
| PORT-a-cath | 12 (5) | 49 (22) | 3 (2) | |
| Tunneled | 54 (21) | 66 (29) | 17 (15) | |
| DVT location, n (%) | ||||
| Brachial | 25 (10) | 13 (6) | <.001ठ| 25 (22) |
| Axillary | 58 (23) | 30 (13) | 33 (28) | |
| Subclavian | 108 (42) | 80 (36) | 40 (34) | |
| Internal jugular | 48 (19) | 80 (36) | 16 (14) | |
| Superior vena cava | 6 (2) | 4 (2) | 2 (2) | |
| Brachiocephalic | 8 (3) | 16 (7) | 0 | |
| Other | 2 (1) | 2 (1) | 0 | |
| Platelet count(× 109/L), median (IQR) | 125 (61-208) | 138 (72-207) | .25§ | 30 (18-71) |
| Anticoagulation, n (%) | ||||
| LMWH | 192 (75) | 178 (79) | .20‡ | NA |
| Bridge to VKA | 24 (9) | 10 (4) | ||
| UFH | 23 (9) | 24 (11) | ||
| Aspirin | 1 (0.4) | 0 | ||
| Other | 15 (6) | 13 (6) |
P values reported are for delayed or no removal vs early removal. Early removal was defined as removal within 48 hours of UE-DVT diagnosis. DVT location refers to most proximal location of the thrombus.
IQR, interquartile range; LMWH, low molecular weight heparin; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; SD, standard deviation; UFH, unfractionated heparin; VKA, vitamin K antagonist.
Student t test.
χ2 test.
Fisher’s exact test.
Mann-Whitney U test.